Monthly pill shows potential as pre-exposure prophylaxis HIV drug candidate

A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, U.S., published in the open-access journal PLOS Biology.